Simplify the Creation, Release, and Management of Multilingual Content

Reduce your cycle times and translation costs while improving resource allocation and achieving greater visibility

Learn More
tpt dig

Drive Consistency and Transparency with GlobalLink TMS

TransPerfect’s translation management system (TMS) helps leading life sciences organizations:

  • Icon Automate Manual Processes

Automate manual tasks

  • Icon Magnifying Glass with a Clock

Ensure a comprehensive audit trail, including a clear record of who made changes and when they were made

  • Icon Checklist 2

Facilitate a collaborative online review process to eliminate the need for an email with marked-up files

  • Icon AI Integrations

Centrally manage and leverage translation memory (TM) and other linguistic assets

  • Icon Data

Capture important data for reporting and KPI metrics

  • Icon Network 2

Integrate with other content repositories

Centralize your content in a web-based, intuitive, and secure platform

Streamlining processes to reduce cycle times and increase efficiency is an increasing trend within the life sciences industry. TransPerfect’s enabling translation technology platform, GlobalLink, automates manual steps, drives consistency through central translation memories (TMs) and linguistic assets, incorporates machine translation (MT) workflows, and offers real-time reporting for greater visibility and control. GlobalLink TMS streamlines the translation process and provides standardization that can accelerate the time-to-market by 40–60% and decrease translation costs by 25–40%.

GlobalLink TMS at a Glance

6 k+

Clients trust GlobalLink


50 %

Reduction in translation costs

40 %

Reduction in cycle times

50 %

Reduction of internal project management and IT dependencies

50 +

Out-of-the-box connectors for automation

Document Check

GxP and CFR 21 Part 11 compliant

Handshake

Key partnerships, including Veeva and Adobe

GlobalLink

Translation Management Technology That Supports Your Growth

Sponsors supporting global operations produce vast amounts of content in need of translation. The complexity of content volume, tight timelines, quality and compliance concerns, administrative burden, and budget constraints all challenge the efficiency of managing content translation at scale.

TransPerfect Life Sciences' TMS solutions help sponsors navigate content complexities by driving process automation, improving TM efficacy and consistency, incorporating MT workflows, and optimizing content review to shorten cycle times and reduce total translation costs.

Trusted by Life Sciences Organizations Big and Small

Join TransPerfect's community of over 1,000 life sciences organizations, including pharma, biotech, CROs, IRBs, and agencies.

20230124-lifesciences-resize-v3_0022_400x160px-hologic_logo.png
untitled_design_4.png
20230124-lifesciences-resize-v3_0016_400x160px-bayer_logo.png
20230124-lifesciences-resize-v3_0015_400x160px-merck_logo.png

Learn Why Leading Life Sciences Organizations Love GlobalLink TMS

Schedule a Demo.

How did you hear about us?
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

News and Press Releases

Our industry experts have in-depth understanding of the challenges, requirements, and goals for life sciences organizations involved in clinical trial management.

XTalks | eCOA: Has It Lived Up to the Promise? A Realistic Assessment for Today's Trials

Despite two decades of technological advancement, the debate between paper and electronic clinical outcome assessments (eCOA) remains unresolved. This webinar revisits the assumptions that continue to shape data collection strategies and examines whether current practice reflects today’s eCOA capabilities or institutional habit. Paper is often framed as the “gold standard,” yet paper-based patient-reported outcome data can be incomplete, error-prone and difficult to ...

XTalks | eCOA: Has It Lived Up to the Promise? A Realistic Assessment for Today's Trials

Top 10 Pharma Company Overhauls Global COA Program,Cutting Costs by 33% and Errors to Near Zero

Inconsistent standards, stretched timelines, and limited visibility were straining a top 10 pharma company's COA program. Discover how TransPerfect Life Sciences' centralization strategy delivered 99.7% accuracy, 40% less PM oversight, and 33% cost savings across the ...

Four Years In: What the EU Clinical Trial Regulation Has (and Hasn't) Delivered

When the EU Clinical Trial Regulation (EU CTR No 536/2014) went live for new submissions on January 31, 2022, it promised to transform how clinical trials are authorized and conducted across Europe: a single submission, one decision, and harmonized oversight. Four years in,...

How to Make Your Academy Succeed at Global Scale—Lessons Learned on What Works and What Doesn’t

Most life sciences and MedTech companies launch a corporate academy with strong strategic intent, whether that’s executive sponsorship, a named platform, a dedicated budget, or a curriculum mapped to business goals. After launch, however, these same organizations all too often ...

IMP Labeling Workflows That Reduce Relabeling Risk and Start-Up Delays

Investigational medicinal product (IMP) labeling sits at the heart of clinical trial supply, impacting departments across pharmaceutical organizations, from clinical operations and regulatory affairs to quality assurance and beyond. When labeling activities are managed across ...

The Missing Link: Why Study Design Makes or Breaks a Clinical Trial

In this episode of LifeSci Talks, Mark Wade, Global Practice Leader at TransPerfect Life Sciences, sits down with Farrell Healion, Founder and Principal Consultant at OptiTrial, to explore why study design is so often the overlooked "missing link" in clinical ...

C3 Summit 2026 - London

Conversations on Clinical Content, C3 Summit is part of a series of events hosted by TransPerfect Life Sciences featuring sessions with expert panels discussing present challenges, strategies, and innovations, as well as insights into future advancements, from R&D to ...